Form 4: Apogee Therapeutics CEO Michael Henderson Sells Shares Under 10b5-1 Plan

Apogee Therapeutics CEO Michael Henderson sold a total of 15,000 shares of common stock on December 4, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Henderson, CEO of Apogee Therapeutics, sold 13,328 shares of common stock at a weighted average price of $46.50 on December 4, 2024.
• He also sold an additional 1,672 shares of common stock at a weighted average price of $47.19 on the same day.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 25, 2023.
• Following these sales, Henderson's direct ownership of Apogee Therapeutics common stock decreased to 1,324,487 shares.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock sales by an executive under a pre-arranged plan. It is neither positive nor negative in itself, but the market reaction could vary.

Risks

• The sale of shares by the CEO could be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Executive stock sales are a common occurrence, and the use of 10b5-1 plans is a standard practice to avoid accusations of insider trading. This filing is a routine disclosure of such activity.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, such as those in the biotechnology sector like Regeneron Pharmaceuticals or Amgen, to manage their stock sales in a compliant manner.
• The reported weighted average prices are within the typical range for stock transactions of this nature.
• The volume of shares sold is not unusual for an executive's pre-planned sales.

Stakeholder Impact

• Shareholders may react to the news of the CEO selling shares, potentially impacting the stock price.

Key Dates

Keywords

Apogee Therapeutics, Michael Henderson, SEC Form 4, stock sale, 10b5-1 plan, insider trading, executive stock transactions